-
Takeda In-Licenses Hunter Syndrome Candidate
Thursday, September 30, 2021 - 7:18am | 243Read More...Takeda Pharmaceutical Company Limited (NYSE: TAK) and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to commercialize JR-141 (pabinafusp alfa) for Hunter syndrome (Mucopolysaccharidosis type II or MPS II). JR-141 is an...
-
Denali's Brain-Penetrant Enzyme Therapy Shows Durable Effect With CNS Impact In Hunter Syndrome
Monday, July 26, 2021 - 6:59am | 329Read More...Denali Therapeutics Inc (NASDAQ: DNLI) announced additional interim data from a Phase 1/2 study evaluating ETV:IDS (DNL310) for the central nervous system (CNS) and peripheral manifestations of Hunter syndrome (MPS II). DNL30 is an investigational brain-penetrant enzyme replacement...
-
Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two Years
Friday, May 14, 2021 - 2:40pm | 322Read More...Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. The data will be...
-
Denali's Enzyme Replacement Therapy Shows Encouraging Biomarker Effects In Early-Stage Hunter Syndrome Study
Friday, February 12, 2021 - 9:54am | 403Read More...Denali Therapeutics Inc (NASDAQ: DNLI) has announced additional interim results from its ongoing Phase 1/2 study evaluating ETV:IDS (DNL310) as a potential brain-penetrant enzyme replacement therapy for Hunter syndrome (MPS II). MPS II is a rare neurodegenerative...
